247 related articles for article (PubMed ID: 30171068)
21. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
22. Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective.
Joish VN; Frech F; Lapuerta P
Clin Ther; 2017 Dec; 39(12):2338-2344. PubMed ID: 29175096
[TBL] [Abstract][Full Text] [Related]
23. Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome.
Halperin DM; Huynh L; Beaumont JL; Cai B; Bhak RH; Narkhede S; Totev T; Duh MS; Neary MP; Cella D
BMC Cancer; 2019 Mar; 19(1):274. PubMed ID: 30922252
[TBL] [Abstract][Full Text] [Related]
24. Treatment of diarrhea in carcinoid syndrome with ondansetron, tropisetron, and clonidine.
Schwörer H; Münke H; Stöckmann F; Ramadori G
Am J Gastroenterol; 1995 Apr; 90(4):645-8. PubMed ID: 7717328
[TBL] [Abstract][Full Text] [Related]
25. Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome.
Koumarianou A; Daskalakis K; Tsoli M; Kaltsas G; Pavel M
J Neuroendocrinol; 2022 Jul; 34(7):e13174. PubMed ID: 35794780
[TBL] [Abstract][Full Text] [Related]
26. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.
Lesén E; Björstad Å; Björholt I; Marlow T; Bollano E; Feuilly M; Marteau F; Welin S; Elf AK; Johanson V
Scand J Gastroenterol; 2018 Dec; 53(12):1509-1518. PubMed ID: 30449217
[TBL] [Abstract][Full Text] [Related]
27. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.
Strosberg JR; Benson AB; Huynh L; Duh MS; Goldman J; Sahai V; Rademaker AW; Kulke MH
Oncologist; 2014 Sep; 19(9):930-6. PubMed ID: 25096997
[TBL] [Abstract][Full Text] [Related]
28. Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea.
Dillon JS; Chandrasekharan C
Future Oncol; 2018 May; 14(12):1155-1164. PubMed ID: 29350062
[TBL] [Abstract][Full Text] [Related]
29. Ondansetron in carcinoid syndrome.
Platt AJ; Heddle RM; Rake MO; Smedley H
Lancet; 1992 Jun; 339(8806):1416. PubMed ID: 1375972
[No Abstract] [Full Text] [Related]
30. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
[TBL] [Abstract][Full Text] [Related]
31. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial.
Pavel M; Hörsch D; Caplin M; Ramage J; Seufferlein T; Valle J; Banks P; Lapuerta P; Sands A; Zambrowicz B; Fleming D; Wiedenmann B
J Clin Endocrinol Metab; 2015 Apr; 100(4):1511-9. PubMed ID: 25636046
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic principles in the management of metastasising carcinoid tumors: drugs for symptomatic treatment.
Gregor M
Digestion; 1994; 55 Suppl 3():60-3. PubMed ID: 7698539
[TBL] [Abstract][Full Text] [Related]
33. Infection with multidrug-resistant Campylobacter coli mimicking recurrence of carcinoid syndrome: a case report of a neuroendocrine tumor patient with repeated diarrhea.
Lagler H; Kiesewetter B; Raderer M
BMC Infect Dis; 2016 Aug; 16():409. PubMed ID: 27519265
[TBL] [Abstract][Full Text] [Related]
34. Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
Pasricha G; Padhi P; Daboul N; Monga DK
Clin Ther; 2017 Nov; 39(11):2146-2157. PubMed ID: 29173655
[TBL] [Abstract][Full Text] [Related]
35. [A prolonged-action somatostatin analog and carcinoid syndrome].
Chayvialle JA
Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
[TBL] [Abstract][Full Text] [Related]
36. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.
Ruszniewski P; Ducreux M; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Bernades P; Rougier P
Gut; 1996 Aug; 39(2):279-83. PubMed ID: 8977344
[TBL] [Abstract][Full Text] [Related]
37. Ondansetron for diarrhea associated with neuroendocrine tumors.
Kiesewetter B; Raderer M
N Engl J Med; 2013 May; 368(20):1947-8. PubMed ID: 23675671
[No Abstract] [Full Text] [Related]
38. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.
Dillon JS; Kulke MH; Hörsch D; Anthony LB; Warner RRP; Bergsland E; Welin S; O'Dorisio TM; Kunz PL; McKee C; Lapuerta P; Banks P; Pavel M
J Gastrointest Cancer; 2021 Mar; 52(1):212-221. PubMed ID: 32146619
[TBL] [Abstract][Full Text] [Related]
39. A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea.
von der Ohe MR; Camilleri M; Kvols LK
Gastroenterology; 1994 May; 106(5):1184-9. PubMed ID: 8174881
[TBL] [Abstract][Full Text] [Related]
40. [Ondansetron in carcinoid syndrome].
Buhl C; Fibbe C; Frenzel H
Dtsch Med Wochenschr; 1992 Nov; 117(47):1821. PubMed ID: 1425313
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
